Persica Pharmaceuticals Announces Collaboration with BackCare

Persica Pharmaceuticals Announces Collaboration with BackCare

London, UK, 24 August 2022 – Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing a breakthrough injectable antibiotic formulation to treat patients suffering from chronic low back pain (CLBP), today announces a new collaboration with BackCare, a charity dedicated to back pain, regardless of cause.

The two organisations share a goal to provide support and relief to patients living with back pain and will provide mutual support around projects aimed at education and research into CLBP.

BackCare, the National Back Pain Association charity provides both education to help prevent avoidable back injury and practical and emotional support to people living with back pain whether caused through wear and tear, injury, musculoskeletal disorders or other serious underlying health conditions.

CLBP is one of the world’s leading causes of disability and an area of significant unmet need. Patients can experience CLBP for several reasons which require different treatment options. There is now substantial evidence that in up to 20% of all CLBP populations, the underlying disease mechanism is localised chronic disc infection with anaerobic bacteria. Persica’s novel approach is based around ground-breaking research, offering a new understanding of this cause of low back pain – and why current treatments are lacking. Long term oral antibiotic treatment as a therapeutic intervention has been shown to address and alleviate the symptoms associated with the infection, particularly in subjects demonstrating bone oedema (Modic type 1) changes.

Persica’s Modic Trial, is a placebo-controlled randomised clinical trial assessing the efficacy of a novel antibiotic formulation, PP353, to treat patients with CLBP associated with Modic 1 changes. The trial will assess patient-reported low back pain and disability and will be conducted across sites in the UK, mainland Europe and New Zealand.

Steve Ruston, Chief Executive Officer of Persica Pharmaceuticals Ltd said: “I am very pleased to establish this collaboration with BackCare, an organisation with 50 years of experience working with people impacted by back pain. With its extensive network, we believe working with BackCare, can help us to reach and potentially improve the lives of a large number of patients suffering from CLBP.”

Denice Logan Rose, Executive Director, of BackCare, said: “We are excited to collaborate with Persica, whose new approach to the treatment of CLBP, if successful, has great potential to impact a significant proportion of people  suffering from this condition, for whom conventional treatments are of little benefit.”


For further information:

Persica Pharmaceuticals

Dr. Steve Ruston (Chief Executive Officer)


Denice Logan Rose (Executive Director)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Genevieve Wilson

Tel: +44 (0)20 3709 5700

About Persica Pharmaceuticals

Persica Pharmaceuticals is a clinical stage pharmaceutical company developing PP353, an injectable antibiotic formulation as a therapeutic intervention to treat patients with CLBP caused by bacterial infection. The company has commenced a Phase Ib clinical study to demonstrate the safety and efficacy of PP353 in CLBP patients in the UK, mainland Europe and New Zealand.

CLBP is the world’s leading global cause of disability1, affecting over 10 per cent of the population in the Western world2, with few treatment options currently available to sufferers.

Persica is headquartered in Kent, UK. For more information visit

About BackCare

The National Association of Back Pain (more commonly known as BackCare) is a charity established over 50 years ago to provide education through awareness programmes and practical and emotional support to people living with back pain, regardless of cause. Today it is proud to have HRH The Prince of Wales as its Patron and the opportunity to touch the lives of many thousands of people, who are living with back pain.

Further information:



Comments are closed.